D
DYN
Dyne Therapeutics, Inc.
18.16
-0.19-1.04%After Hours: 18.16 0.00 0.00%16:10 04/07 EDT
OPEN/PREV CLOSE18.99/18.16
TODAY RANGE17.91-19.23
VOL1.12M
MARKET CAP3.03B
52 WEEK RANGE6.36-25.00
AVG VOL (3M)2.18M
% TURNOVER0.68%
TURNOVER--
P/E (TTM)-5.2907
% RANGE7.27%
EPS(TTM)-3.4740
P/E(FORWARD)-6.1444
P/B3.119
BVPS5.89
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.85B
SHARES OUTSTANDING165.03M
NEXT EARNINGS05/06-05/11
FREE FLOAT154.96M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
A Look At Dyne Therapeutics (DYN) Valuation After Strong Recent Share Price Momentum
Simply Wall St·6d ago
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders
TipRanks·04/02 02:02
Insider Scoop: Dyne Therapeutics Director Makes a Bold New Purchase
Seeking Alpha·03/19 18:37
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Simply Wall St·03/16 23:24
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)?
TipRanks·03/16 11:35
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)
Simply Wall St·03/14 18:36
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case
TipRanks·03/14 02:08
Top Dyne Therapeutics Insider Quietly Boosts Stake in Bold New Move
Reuters·03/13 20:47
Dyne Therapeutics Director Brian S. Posner Acquires Common Shares
Reuters·03/13 20:36
Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares
Simply Wall St·03/13 14:17
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data
Reuters·03/11 21:28
Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares
Benzinga·03/10 15:06
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Same Industry
Name/Symbol
Change%
Price